75 results about "Rheumatic fever" patented technology

The present invention relates to a streptococcal octapeptide AXYLXXLN, and preferably to the octapeptide AXYLZZLN, designated as peptide associated with rheumatic fever (PARF) that, through its interaction with human collagen, plays a crucial role in the pathogenesis of rheumatic fever. PARF therefore represents a marker for rheumatic fever associated strains and provides a target for therapies, and in particular preventive therapies.

Recombinant hybrid streptococcal M protein antigens are provided which elicit protective antibodies against Group A streptococci and prevent rheumatic fever. Recombinant hybrid genes that encode the antigen are provided. Vaccine compositions and methods of administering the compositions are provided to elicit immunity against Group A streptococci.

Disclosed is a pharmaceutical composition for preventing or treating TRPV1 activity-related or inflammation-related, diseases or conditions, containing a Maillard peptide separated from well-aged traditional soy sauce as an active ingredient. The Maillard peptide in the present invention functions both as a TRPV1 agonist and a TRPV1 antagonist, and further functions as a TRPV1 activity modulator. Therefore, the Maillard peptide can be used for preventing or treating TRPV1 activity-related diseases such as pain, neurological diseases, urgent defecation, inflammatory bowel disease, respiratory diseases, urinary incontinence, overactive bladder, neurogenic / allergic / inflammatory skin diseases, skin, eye or mucosal irritation, hyperacusis, tinnitus, vestibular hypersensitivity, heart disease, etc. The Maillard peptide can further inhibit COX-2 activity, and therefore can be effectively used for preventing or treating inflammation-related diseases or conditions such as rheumatic fever, influenza, cold, throat pain, headaches, toothaches, sprains, neuralgia, synovitis, rheumatoid arthritis, degenerative arthropathies, gout, ankylosing spondylitis, psoriasis, dermatitis, etc.

VACCIN AGAINST GROUP A BETA HEMOLYTIC STREPTOCOCCUS AND RESPECTIVE PROCESS FOR OBTAINING THEREOF, which predicts the production of recombinant protein cloned from the gene emm5, which contains a sequence of oligonucleotides corresponding to 52 and / or 87 amino acid residues capable of protection, isolated after the sequential molecular identification of the epitopes from the M protein carboxy-terminal region, differing in 01 amino acid residue, identified by antibodies and T lymphocytes of health human beings and of patients carriers of rheumatic fever, capable of generating a protective response by antibodies depending on the T lymphocytes; prevention of the development of the autoimmune disease by the selected epitope was evaluated in vitro with T lymphocytes from the cardiac tissue of patients with lesions arising out of rheumatic fever.

The invention provides a Zhuang medicine composition with a treatment effect on acute gouty arthritis, Zhuang medicine particles and a preparation method of the Zhuang medicine composition and the Zhuang medicine particles, and relates to the technical field of ethnic medicines. The Zhuang medicine composition is composed of glabrous sarcandra herb, rhizoma dioscoreae hypoglaucae, plantain herb, polygonum cuspidatum, cynanchum paniculatum, garden balsam stem, honeysuckle stem and liquorice, and clinical application results prove that the Zhuang medicine composition has the effects of clearing heat toxin, removing dampness toxin, dispelling wind toxin, relieving swelling pain, adjusting water channels, dredging long channels and fire channels, and has a remarkable curative effect on gout (gout) caused by wind-damp heat toxin. The Zhuang medicine composition and the Zhuang medicine granules based on the Zhuang medicine composition have very good curative effects on arthralgia, redness and swelling, scorching heat, unfavorable flexion and extension, blood uric acid increase, tophus and the like, and particularly, the Zhuang medicine composition and the Zhuang medicine granules based on the Zhuang medicine composition can be used for treating gouty arthritis induced by MSU crystals, and have the characteristics of multiple targets and low toxicity.

The invention provides a traditional Chinese medicine composition for treating osteoarthritis and a preparation method thereof. The traditional Chinese medicine composition is prepared from from the following raw material medicines in parts by weight: 10-20 parts of poria cocos, 5-15 parts of cassia twigs, 2-8 parts of rhizoma atractylodis, 2-8 parts of cortex phellodendri, 2-8 parts of radix stephaniae tetrandrae, 2-8 parts of polyporus umbellatus, 2-8 parts of rhizoma drynariae, 5-15 parts of rhizoma corydalis and 3-9 parts of radix cyathulae. The composition disclosed by the invention has the functions of tonifying spleen, promoting diuresis, dispelling wind, clearing heat, dredging collaterals and relieving pain, and is clinically applicable to patients suffering from rheumatic fever arthralgia in the attack stage of knee osteoarthritis, wherein the patients have the symptoms of swelling, pain, unfavorable flexion and extension and even local pyrexia, redness and swelling of joints, fat and big tongue body with tooth prints, yellow and greasy tongue coating and few pulse strings. When the composition provided by the invention is used for intervening in a rabbit with knee osteoarthritis, results show that the composition can relieve symptoms like joint swelling and skin temperature rise of the rabbit with knee osteoarthritis, improve joint functions, reduce the contents of IL-1[beta], TNF[alpha], PGE2 and NO in joints, relieve synovitis and delay the progress of knee osteoarthritis. Clinical observation results show that the composition provided by the invention has theeffects of relieving swelling and pain and improving joint functions for patients with knee osteoarthritis.

The use of 1-MNA or a pharmaceutically acceptable salt thereof for reducing the risk of cardiovascular disease in a subject with a blood or serum CRP level of less than 10 mg / L. The disclosure also discloses the use of 1-MNA or a pharmaceutically acceptable salt thereof in the amount effective for reducing the blood or serum CRP level for the treatment of diseases such as rheumatoid arthritis, colon cancer, breast cancer, lung cancer, infection, inflammatory bowel disease, lupus erythematosus, pneumococcal pneumonia, rheumatic fever, tuberculosis, renal failure, amyotrophic lateral sclerosis,or a combination thereof.

The invention discloses a traditional Chinese medicine composition for treating arthritis caused by rheumatic fever. The traditional Chinese medicine composition is prepared from the following main raw materials in parts by weight: 5-15 parts of radix scrophulariae, 15-25 parts of golden cypress, 10-20 parts of Ligusticum wallichii, 3-5 parts of radix angelicae pubescentis, 4-11 parts of cassia twig, 8-16 parts of Chinese Starjasmine Stem, 7-15 parts of fructus forsythiae, 5-15 parts of Lonicera japonica, 3-7 parts of nux vomica, 6-10 parts of loranthus parasiticus, 3-9 parts of Artemisia anomala, 6-9 parts of ephedra, 0.5-1.5 parts of zaocys dhumnade, 4-8 parts of cynanchum paniculatum, 3-8 parts of dipsacus root and 5-10 parts of pepper. The traditional Chinese medicine composition for treating arthritis caused by rheumatic fever disclosed by the invention has the functions of promoting blood circulation to remove blood stasis, clearing and activating the channels and collaterals, strengthening tendons and bones, and eliminating stagnant blood and relieving pains, the medical herbs resource of medicine materials is easily available, the cost is low, the selected materials are mild in drug property, and no economic or body burden is increased for a user with long-term use.

The invention provides a spiraea salicifolia stem and branch anti-rheumatoid-arthritis effective part and a preparation method and application thereof.According to the effective part, spiraea salicifolia stems and branches serve as raw materials, extract is obtained after 60% ethyl alcohol reflux extraction and ethyl alcohol pressure reduction recovery, the extract is purified with macroporous adsorption resin, and the total lignanoside effective part is obtained.The sum of weights of (+)-8'-hydroxy pinoresinol-8'-O-beta-d-glucopyranoside, (7R,8S)-dihydro dehydrogenation bis-coniferyl alcohol-9'-O-beta-d-glucopyranoside, (+)-lyonia ovalifolia tree ring lignans-9-O-beta-d-glucopyranoside and (+)-isolariciresinol-9-O-beta-d-pyran xyloside in the effective part ranges from 40% to 50%.The effective part is determined through the method that a modern separation means and pharmacological activity screening are combined, the ingredients of obtained effective part are clear, the content of active ingredients is high, it is shown through the in-vitro and in-vivo experiment results that the spiraea salicifolia stem and branch anti-rheumatoid-arthritis effective part inhibits generation of pro-inflammatory cytokine tumor necrosis factor-alpha, interleukin-1 beta and interleukin-6 to achieve the effect of treating rheumatoid arthritis.

The invention discloses Chinese medicine external lotion for treating infantile eczema. In china, the infantile eczema is medically called milk ringworm and also called embryo ringworm. The natural disposition is not tolerant, the skin is tender and lovely, the transformation of the spleen and the stomach is failed, the body of the infant is internally suffered from embryo fire damp heat and is externally invaded by rheumatic fever evil, and the internal reason and the external reason are blocked by the skin so as to cause the disease. According to the Chinese medicine external lotion, the Chinese medicines such as tangut barberry barks, felworts, Guangdong longhairy antenoron herbs, Chinese glochidion leaves, climbing groundsel herbs, sturnus roseus, golden larch barks, sinkiang arnebia roots, agaric, honewort stem and leaf and henry clematis roots are selected and decocted with water to prepare external lotion. A clinical test in hospital shows that the total effective rate is 95.0 percent, and the efficiency is superior to that of a control group.